|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: EAU guidelines on prostate cancer. part 1:
Screening, diagnosis, and local treatment with curative
intent-update 2013. Eur Urol. 65:124–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Egidi MG, Cochetti G, Serva MR, Guelfi G,
Zampini D, Mechelli L and Mearini E: Circulating microRNAs and
kallikreins before and after radical prostatectomy: Are they really
prostate cancer markers? Biomed Res Int. 2013:2417802013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Global Burden of Disease Cancer
Collaboration, . Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, mortality, years
of life lost, years lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gupta M, McCauley J, Farkas A, Gudeloglu
A, Neuberger MM, Ho YY, Yeung L, Vieweg J and Dahm P: Clinical
practice guidelines on prostate cancer: A critical appraisal. J
Urol. 193:1153–1158. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Antognelli C, Mezzasoma L, Mearini E and
Talesa VN: Glyoxalase 1-419C>A variant is associated with
oxidative stress: Implications in prostate cancer progression. PLoS
One. 8:e740142013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Antognelli C, Mezzasoma L, Fettucciari K,
Mearini E and Talesa VN: Role of glyoxalase I in the proliferation
and apoptosis control of human LNCaP and PC3 prostate cancer cells.
Prostate. 73:121–132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bazarbashi S, Bachour M, Bulbul M,
Alotaibi M, Jaloudi M, Jaafar H, Mukherji D, Farah N, Alrubai T and
Shamseddine A: Metastatic castration resistant prostate cancer:
Current strategies of management in the middle East. Crit Rev Oncol
Hematol. 90:36–48. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mearini E, Antognelli C, Del Buono C,
Cochetti G, Giannantoni A, Nardelli E and Talesa VN: The
combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular
markers of prostate cancer. Biomarkers. 14:235–243. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Egidi MG, Cochetti G, Guelfi G, Zampini D,
Diverio S, Poli G and Mearini E: Stability assessment of candidate
reference genes in urine sediment of prostate cancer patients for
miRNA applications. Dis Markers. 2015:9735972015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Talesa VN, Antognelli C, Del Buono C,
Stracci F, Serva MR, Cottini E and Mearini E: Diagnostic potential
in prostate cancer of a panel of urinary molecular tumor markers.
Cancer Biomark. 5:241–251. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rende M, Rambotti MG, Stabile AM, Pistilli
A, Montagnoli C, Chiarelli MT and Mearini E: Novel localization of
low affinity NGF receptor (p75) in the stroma of prostate cancer
and possible implication in neoplastic invasion: An
immunohistochemical and ultracytochemical study. Prostate.
70:555–561. 2010.PubMed/NCBI
|
|
14
|
MacFarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kanwal R, Plaga AR, Liu X, Shukla GC and
Gupta S: MicroRNAs in prostate cancer: Functional role as
biomarkers. Cancer Lett. 407:9–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartel D: MicroRNAs: Genomics, biogenesis,
mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao L, Lu X and Cao Y: MicroRNA and
signal transduction pathways in tumor radiation response. Cell
Signal. 25:1625–1634. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu C, Kelnar K, Liu B, Chen X,
Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et
al: The microRNA miR-34a inhibits prostate cancer stem cells and
metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guelfi G, Cochetti G, Stefanetti V,
Zampini D, Diverio S, Boni A and Mearini E: Next generation
sequencing of urine exfoliated cells: An approach of prostate
cancer microRNAs research. Sci Rep. 8:71112018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tucci P, Agostini M, Grespi F, Markert EK,
Terrinoni A, Vousden KH, Muller PA, Dötsch V, Kehrloesser S, Sayan
BS, et al: Loss of p63 and its microRNA-205 target results in
enhanced cell migration and metastasis in prostate cancer. Proc
Natl Acad Sci USA. 109:15312–15317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cochetti G, Poli G, Guelfi G, Boni A,
Egidi MG and Mearini E: Different levels of serum microRNAs in
prostate cancer and benign prostatic hyperplasia: Evaluation of
potential diagnostic and prognostic role. Onco Targets Ther.
9:7545–7553. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and down-regulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang F, Mao A, Tang J, Zhang Q, Yan J,
Wang Y, Di C, Gan L, Sun C and Zhang H: microRNA-16-5p enhances
radiosensitivity through modulating Cyclin D1/E1-pRb-E2F1 pathway
in prostate cancer cells. J Cell Physiol. 234:13182–13190. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bonci D, Coppola V, Musumeci M, Addario A,
Giuffrida R, Memeo L, DUrso L, Pagliuca A, Biffoni M, Labbaye C, et
al: The miR-15a-miR-16-1 cluster controls prostate cancer by
targeting multiple oncogenic activities. Nat Med. 14:1271–1277.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang L, Graham P, Ni J, Hao J, Bucci J,
Cozzi P and Li Y: Targeting PI3K/Akt/mTOR signaling pathway in the
treatment of prostate cancer radioresistance. Crit Rev Oncol
Hematol. 96:507–517. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang L, Graham PH, Hao J, Ni J, Bucci J,
Cozzi PJ, Kearsley JH and Li Y: PI3K/Akt/mTOR pathway inhibitors
enhance radiosensitivity in radioresistant prostate cancer cells
through inducing apoptosis, reducing autophagy, suppressing NHEJ
and HR repair pathways. Cell Death Dis. 5:e14372014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Taylor BS, Schultz N, Hieronymus H,
Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva
B, et al: Integrative genomic profiling of human prostate cancer.
Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang F and Wu Z: Significantly altered
expression of miR-511-3p and its target AKT3 has negative
prognostic value in human prostate cancer. Biochimie. 140:66–72.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: Determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiang X and Wang Z: miR-16 targets SALL4
to repress the proliferation and migration of gastric cancer. Oncol
Lett. 16:3005–3012. 2018.PubMed/NCBI
|
|
32
|
Zhang H, Yang K, Ren T, Huang Y, Tang X
and Guo W: miR-16-5p inhibits chordoma cell proliferation, invasion
and metastasis by targeting Smad3. Cell Death Dis. 9:6802018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Krell A, Wolter M, Stojcheva N, Hertler C,
Liesenberg F, Zapatka M, Weller M, Malzkorn B and Reifenberger G:
MiR-16-5p is frequently down-regulated in astrocytic gliomas and
modulates glioma cell proliferation, apoptosis and response to
cytotoxic therapy. Neuropathol Appl Neurobiol. 45:441–458.
2019.PubMed/NCBI
|
|
34
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Swanton C: Cell-cycle targeted therapies.
Lancet Oncol. 5:27–36. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Betel D, Koppal A, Agius P, Sander C and
Leslie C: Comprehensive modeling of microRNA targets predicts
functional non-conserved and non-canonical sites. Genome Biol.
11:R902010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Anders G, Mackowiak SD, Jens M, Maaskola
J, Kuntzagk A, Rajewsky N, Landthaler M and Dieterich C: doRiNA: A
database of RNA interactions in post-transcriptional regulation.
Nucleic Acids Res. 40((Database Issue)): D180–D186. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Miranda KC, Huynh T, Tay Y, Ang YS, Tam
WL, Thomson AM, Lim B and Rigoutsos I: A pattern-based method for
the identification of MicroRNA binding sites and their
corresponding heteroduplexes. Cell. 126:1203–1217. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cancer Genome Atlas Research Network.
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome
atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42((Database Issue)): D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nitulescu GM, Van De Venter M, Nitulescu
G, Ungurianu A, Juzenas P, Peng Q, Olaru OT, Gradinaru D, Tsatsakis
A, Tsoukalas D, et al: The Akt pathway in oncology therapy and
beyond (Review). Int J Oncol. 53:2319–2331. 2018.PubMed/NCBI
|
|
42
|
Lin HP, Lin CY, Huo C, Jan YJ, Tseng JC,
Jiang SS, Kuo YY, Chen SC, Wang CT, Chan TM, et al: AKT3 promotes
prostate cancer proliferation cells through regulation of Akt,
B-Raf, and TSC1/TSC2. Oncotarget. 6:27097–27112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang G, Zhao D, Spring DJ and DePinho RA:
Genetics and biology of prostate cancer. Genes Dev. 32:1105–1140.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mearini E, Poli G, Cochetti G, Boni A,
Egidi MG and Brancorsini S: Expression of urinary miRNAs targeting
NLRs inflammasomes in bladder cancer. Onco Targets Ther.
10:2665–2673. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Celano M, Rosignolo F, Maggisano V, Pecce
V, Iannone M, Russo D and Bulotta S: MicroRNAs as biomarkers in
thyroid carcinoma. Int J Genomics. 2017:64965702017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wiggins JF, Ruffino L, Kelnar K, Omotola
M, Patrawala L, Brown D and Bader AG: Development of a lung cancer
therapeutic based on the tumor suppressor microRNA-34. Cancer Res.
70:5923–5930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Haghi M, Taha MF and Javeri A: Suppressive
effect of exogenous miR-16 and miR-34a on tumorigenesis of breast
cancer cells. J Cell Biochem. 120:13342–13353. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen T, Xiao Q, Wang X, Wang Z, Hu J,
Zhang Z, Gong Z and Chen S: miR-16 regulates proliferation and
invasion of lung cancer cells via the ERK/MAPK signaling pathway by
targeted inhibition of MAPK kinase 1 (MEK1). J Int Med Res.
47:5194–5204. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dong JT, Boyd JC and Frierson HF Jr: Loss
of heterozygosity at 13q14 and 13q21 in high grade, high stage
prostate cancer. Prostate. 49:166–171. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bonci D and De Maria R: miR-15/miR-16
loss, miR-21 upregulation, or deregulation of their target genes
predicts poor prognosis in prostate cancer patients. Mol Cell
Oncol. 3:e11097442015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ciccarese C, Massari F, Iacovelli R,
Fiorentino M, Montironi R, Di Nunno V, Giunchi F, Brunelli M and
Tortora G: Prostate cancer heterogeneity: Discovering novel
molecular targets for therapy. Cancer Treat Rev. 54:68–73. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Morgan TM, Koreckij TD and Corey E:
Targeted therapy for advanced prostate cancer: Inhibition of the
PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 9:237–249. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bedolla R, Prihoda TJ, Kreisberg JI, Malik
SN, Krishnegowda NK, Troyer DA and Ghosh PM: Determining risk of
biochemical recurrence in prostate cancer by immunohistochemical
detection of PTEN expression and Akt activation. Clin Cancer Res.
13:3860–3867. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Heitman J: On the discovery of TOR as the
target of rapamycin. PLoS Pathog. 11:e10052452015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zarogoulidis P, Lampaki S, Turner JF,
Huang H, Kakolyris S, Syrigos K and Zarogoulidis K: mTOR pathway: A
current, up-to-date mini-review (Review). Oncol Lett. 8:2367–2370.
2014. View Article : Google Scholar : PubMed/NCBIPubMed/NCBI
|
